These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33333207)

  • 1. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    Higashi-Kuwata N; Hayashi S; Kumamoto H; Ogata-Aoki H; Das D; Venzon D; Hattori SI; Bulut H; Hashimoto M; Otagiri M; Takamune N; Kishimoto N; Davis DA; Misumi S; Kakuni M; Tanaka Y; Mitsuya H
    J Hepatol; 2021 May; 74(5):1075-1086. PubMed ID: 33333207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
    Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
    Hayashi S; Higashi-Kuwata N; Das D; Tomaya K; Yamada K; Murakami S; Venzon DJ; Hattori SI; Isogawa M; Sarafianos SG; Mitsuya H; Tanaka Y
    Antiviral Res; 2020 Apr; 176():104744. PubMed ID: 32084506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
    Takamatsu Y; Tanaka Y; Kohgo S; Murakami S; Singh K; Das D; Venzon DJ; Amano M; Higashi-Kuwata N; Aoki M; Delino NS; Hayashi S; Takahashi S; Sukenaga Y; Haraguchi K; Sarafianos SG; Maeda K; Mitsuya H
    Hepatology; 2015 Oct; 62(4):1024-36. PubMed ID: 26122273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
    Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
    J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.
    Yasutake Y; Hattori SI; Kumamoto H; Tamura N; Maeda K; Mitsuya H
    Sci Rep; 2024 Jul; 14(1):15742. PubMed ID: 38977798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
    Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
    J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
    Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
    Margeridon-Thermet S; Shulman NS; Ahmed A; Shahriar R; Liu T; Wang C; Holmes SP; Babrzadeh F; Gharizadeh B; Hanczaruk B; Simen BB; Egholm M; Shafer RW
    J Infect Dis; 2009 May; 199(9):1275-85. PubMed ID: 19301976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
    Rawal RK; Konreddy AK; Chu CK
    Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
    Mukaide M; Tanaka Y; Shin-I T; Yuen MF; Kurbanov F; Yokosuka O; Sata M; Karino Y; Yamada G; Sakaguchi K; Orito E; Inoue M; Baqai S; Lai CL; Mizokami M
    Antimicrob Agents Chemother; 2010 Feb; 54(2):882-9. PubMed ID: 19933798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
    Liu Y; Zhou Y; Li X; Niu M; Chen R; Shao J; Si L; Luo D; Lin Y; Li L; Zhang K; Xiao X; Xu Z; Liu M; Lu M; Zoulim F; Xu D
    Emerg Microbes Infect; 2019; 8(1):354-365. PubMed ID: 30866789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
    Walsh AW; Langley DR; Colonno RJ; Tenney DJ
    PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
    Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of an entecavir-resistant hepatitis B virus variant.
    Yatsuji H; Hiraga N; Mori N; Hatakeyama T; Tsuge M; Imamura M; Takahashi S; Fujimoto Y; Ochi H; Abe H; Maekawa T; Suzuki F; Kumada H; Chayama K
    J Med Virol; 2007 Dec; 79(12):1811-7. PubMed ID: 17935165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants.
    Singh US; Mulamoottil VA; Chu CK
    Med Res Rev; 2018 May; 38(3):977-1002. PubMed ID: 29406612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
    Rhee SY; Margeridon-Thermet S; Nguyen MH; Liu TF; Kagan RM; Beggel B; Verheyen J; Kaiser R; Shafer RW
    Antiviral Res; 2010 Dec; 88(3):269-75. PubMed ID: 20875460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.
    Ishibane M; Hashimoto H; Kaneko M; Saito S; Pae S; Saito S; Reien Y; Hirayama Y; Higashi-Kuwata N; Mitsuya H; Anzai N
    J Pharmacol Sci; 2022 Dec; 150(4):201-203. PubMed ID: 36344041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.